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Background: Hip arthroplasty and revision surgery is growing exponentially in OECD countries, but rates
vary between countries.
Methods: We extracted economic data and utilization rates data about hip arthroplasty done in OECD
countries between 1990 and 2011. Absolute number of implantations and compound annual growth rates
were computed per 100,000 population and for patients aged 65 years old and over and for patients aged
64 years and younger.
Results: In the majority of OECD countries, there has been a signiﬁcant increase in the utilization of total
hip arthroplasty in the last 10 years, but rates vary to a great extent: In the United States, Switzerland,
and Germany the utilization rate exceeds 200/100,000 population whereas in Spain and Mexico rates are
102 and 8, respectively. There is a strong correlation between gross domestic product (GDP) and health
care expenditures per capita with utilization rate. Utilization rates in all age groups have continued to
rise up to present day. A seven fold higher growth rate was seen in patients aged 64 years and younger as
compared to older patients.
Conclusion: We observed a 38-fold variation in the utilization of hip arthroplasty among OECD countries,
correlating with GDP and health care expenditures. Over recent years, there has been an increase in the
utilization rate in most countries. This was particularly evident in the younger patients. Due to increasing
life expectancy and the disproportionally high use of arthroplasty in younger patients we expect an
exponential increase of revision rate in the future.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis is one of the 10 most disabling diseases in
developed countries and worldwide affects approximately 10% of
men and 18% of women aged older than 60 years1. The WHO esti-
mates that ageing populations and increasing life expectancy will
make osteoarthritis the fourth leading cause of disability in 20202,3.
Total hip arthroplasty (THA), can provide effective relief for patients
with osteoarthritis of the hip where conservative treatment pat-
terns have failed. Despite worldwide variations in cost4, arthro-
plasty does appear to be cost effective in the long term5.C. Pabinger, Medical Univer-
. Tel: 43-316-908204-0; Fax:
graz.at, M.pabinger@opz.at
ternational. Published by Elsevier LArthroplasty is also being used more frequently in the emergency
setting with those patients with hip fractures6,7.
The use of speciﬁc endoprostheses with unfavourable results
has lead to safety concerns among hip surgeons8,9, but the estab-
lishment of national joint registers has improved knowledge and
the quality of hip implants10.
To our knowledge no study has been performed analysing
recent data and the different utilization rates of hip arthroplasty
across countries and over time. In addition, it remains unclear why
and how much utilization and growth rates of hip arthroplasty
differ among countries.
Therefore, the goal of the study is to analyse the historical and
epidemiological trend of hip arthroplasty utilization rates across
countries using Organisation for Economic Co-operation and Devel-
opment (OECD) health data by discussing the following questions:
(a) What is the incidence of primary hip arthroplasty in OECD
countries according to age and economic parameters?td. All rights reserved.
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time?
(c) Which trends can be derived to predict the future use of hip
arthroplasty?
Material and methods
We extracted economic variables and medical data about hip
arthroplasty done in OECD countries between 1990 and 2011 from
the OECD health data 2013 databases11. However, the majority of
datawere reported later than 2005 andwe therefore focused on the
time period between 2005 and 2011 or the latest available. We
retrieved the following variables for hip replacement which is
internationally identiﬁed by ICD-9-CM codes 81.51 (total replace-
ment), 81.52 (partial replacement) and 81.53 (revision) from OECD
data base: Inpatient cases per 100,000 population and total pro-
cedures per 100,000 population (both variables also for patients
aged 65 years old and over), total population and population aged
65 years and over, annual gross domestic product (GDP) per capita
and annual health care expenditures per capita. Access to essential
care was retrieved from United Nations webpage12.
Data validation for the different variables was done as follows:
Economic and population data appeared in multiple OECD data-
bases and were similar. No differences exceeding 5% were found
between inpatient cases and total procedures (including in- and
outpatient cases). For Australia and Mexico, only total procedures
per 100,000 population were reported. Furthermore OECD data
were compared with register data, where available and differences
did not exceed 5% as well13.
A Pearson correlation between medical and economic data was
done.
In order to compare growth rates across countries and over time
we calculated the compound annual growth rate (CAGR) as the xth
root of the total percentage growth rate, where x is the number of
observed years:
CAGR ¼ ðvalue last year=value first yearÞ^ ð1=#yearsÞ  1
We separated the patients into two age groups e for “patients
aged 65 years old and over” and for “patients aged 64 years and
younger”. Numbers and rates per 100,000 population in “patients
aged 64 years and younger” were calculated as the total number of
hip arthroplasties minus the number of implants in patients aged
65 years and older.
OECD health database reports “rates” in the meaning of “inci-
dence”, which equals “inpatient cases per 100,000 total population”
for everyagegroup. In this case, the denominator is always the “total
population” for all age groups, while the numerator changes ac-
cording to age group. This deﬁnition leads to the phenomenon that
total rate is much higher than the rates of the subgroups might
suggest (Tables IeIII): In 2011 inAustria for example, total utilization
rate per 100,000 total population is 273 and rate of patients aged 65
old and over is 154 and rate of patients aged 64 old and under is 119.
One would assume at ﬁrst sight, that total rate would be a value
between 119 and 154 and not be 273, but the confusion is due to the
fact, that there are 1.5 million people of age 65 and over and 6.9
million people of age 64 and under. According to OECD, the values
are always divided by 100,000 of total population, which is 8.4
millions in Austria. We therefore distinguish between “incidence”,
according to OECD deﬁnition and introduced a new parameter,
named “mean utilization rate”, where numerator and denominator
refer to the same group of population. Using this deﬁnition, values
from the different age groups can be compared and the total “mean
utilization rate” ranges between the age-speciﬁc “mean utilization
rates”: In the example of Austria, 12,972 implants in the group ofpatients aged 65 years and older (1.5 million people) equal an inci-
dence of 154 (12,972 implants/8,400,000 total population
 100,000) or a mean utilization rate of 865 (12,972 implants/
1,500,000population aged65 andover100,000). This is compared
to an incidence of 119 (9900 implants/8,400,000 total
population  100,000) and a mean utilization rate of 144 (9900
implants/6,930,000 aged64 old and less 100,000) inpatients aged
64 old and less. Therefore, patients aged 65 and older present a 30%
higher incidence for a hip arthroplasty as compared to younger
patients, which means that mean utilization rate in this group of
patients is actually six times higher.
Results
The OECD health database contains speciﬁc data relating to hip
arthroplasty for 32 countries. Canada, Denmark and Finland have
continuously reported data since 1990. The majority of countries
(27) have reported valid data since 2005 (Table I). Five countries
(Chile, Czech Republic, Greece, Iceland and Slovak Republic) had to
be excluded due to poor data availability.
The number of hip arthroplasties per 100,000 population
increased since 2000 (Fig. 3) but varies between individual OECD
countries by a factor of 38. The latest available incidence rates showa
broad range from306 hip replacement cases per 100,000 population
in Switzerland to eight per 100,000 population in Mexico. Similar
differences can be demonstrated in the older group. In Switzerland
180 hip procedures in the population over age of 65 years are per-
formedper100,000 total population,whereasKorea reports 15 cases
for the same population (Table II). Switzerland, Germany andAustria
show the highest utilization rates with 286e306 cases per 100,000
population, followed by Belgium, Sweden and Denmark with 225e
237, whereas the USA report 204, respectively.
Annual GDP per capita ranged from 18,321 (Mexico) to 88,276
(Luxembourg) and annual health care expenditures per capita
ranged from 620 USD (Mexico) to 9121 (Switzerland), which
accounted for 3% (Mexico) to 17% (Switzerland) of GDP expendi-
tures. Access to essential care was 100% in all countries, except for
Mexico with 46%, respectively.
A strong correlation (r ¼ .764, P < .001) was found between
utilization rate of hip arthroplasty and health care expenditures
and a signiﬁcant and moderate correlation (r ¼ .642, P < .001) was
found between utilization rate and GDP: Countries with a higher
GDP per capita and higher health care expenditures had a signiﬁ-
cantly higher utilization rate of hip arthroplasty (Fig. 4).
There was a 23% rise in the total number of hip arthroplasties
performed between 2005 and 2011 in OECD, while population grew
only by 4% during the same time frame. This increase is attributed
to the increasing use of arthroplasty in younger patients (þ35%)
(Table III) compared to the older population (þ16%) (Table II). This is
in stark contrast to population growth during the same time frame,
which was 3% and 12%, respectively (Fig. 1). CAGR of “mean utili-
zation rate” is seven times higher in younger patients than in older
ones (3.9% vs 0.6%).
Korea and Poland show the highest growth rates of hip
arthroplasty. In contrast, Ireland shows massive decreasing utili-
zation rates despite the population grows slightly. In Estonia,
Finland and New Zealand as well a decline was noted in the use of
hip arthroplasty in patients aged 65 or older (Fig. 2).
There was a trend for a higher CAGR in countries with a lower
utilization rate as compared to countries with a higher utilization
rate that demonstrated lower CAGR values.
The signiﬁcant increase in total utilizations is attributed to the
increasing use of hip arthroplasty in patients aged less than 65
years, where CAGR rates are higher as compared to older
patients.
Table I
Total utilization rate of hip arthroplasty per 100,000 population from 2000 to 2011
Population
in 2011
[Mio]
Data available
since year
Inpatient cases per 100,000 total population Total number
of implants
in 2011
Health
expenditure
per capita [$]
GDP per
capita [$]
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Australia 22.3 1993 125 136 140 145 148 148 151 155 154 163 167 171z 38,063 5939 44,784
Austria 8.4 2002 225 239 248 251 254 257 263 260 270 273 22,963 5280 43,848
Belgium 11.0 2005 237 236 239 245 230 236 234z 25,867 4962 40,068
Canada 34.5 1990 79 82 99 105 110 117 119 119 122 124 125 127z 43,644 5630 41,455
Denmark 5.6 1990 162 166 190 184 198 206 209 210 198 236 225 229z 12,743 6648 42,176
Estonia 1.3 2003 87 80 81 86 85 90 88 85 82 1095 987 23,625
Finland 5.4 1990 174 179 189 197 187 211 220 206 220 215 226 225 12,097 4325 38,282
France 63.2 1997 207 212 215 214 212 217 215 217 220 223 225 230 145,157 4952 36,249
Germany 81.8 2005 255 260 268 277 283 284 286 233,696 4875 41,231
Hungary 10.0 2005 110 109 95 101 100 96 115 11,467 1085 22,011
Ireland 4.6 1995 132 126 132 132 133 138 135 129 120 117 120 118 5405 4542 43,579
Israel 7.8 2000 45 50 48 49 51 50 52 53 52 51 52 53z 4085 2426 29,830
Italy 60.7 2001 130 137 140 146 148 152 153 153 153 156 157 95,093 3436 33,117
Korea 49.8 2004 10 11z 12 15 16 17 18 17 8612 1616 30,800
Luxembourg 0.5 1998 194 201 221 219 227 220 216 233 219 219 206 228 1181 8798 88,276
Mexico 109.2 1995 4 6 6 6 6 6 7 7 7 8 8 8 8628 620 18,321
Netherlands 16.7 1995 167 174 183 190 193 191 193 196 204 207 216 220z 36,670 5995 43,146
New Zealand 4.4 1996 119 117 109 105 129 133 135 146 144 145 143 141 6202 3666 32,898
Norway 5.0 1996 171 186 187 212 192 203 197 231 232 242 250z 258z 12,791 8987 65,638
Poland 38.5 2005 40 47 46 52 58 63 75 29,048 899 22,167
Portugal 10.6 1993 72 78 87 76 80 77 82 81 85 88 90z 93z 9783 2311 25,275
Slovenia 2.1 2005 157 175 164 184 182 158 187 3836 2218 25,323
Spain 46.2 1997 72 79 81 82 82 87 89 93 91 93 98 102 47,006 3027 32,081
Sweden 9.4 2005 210 210 212 220 234 237 233 22,016 5331 43,176
Switzerland 7.9 2002 241 251 260 266 274 289 292 296 304 306 24,188 9121 53,733
United Kingdom 63.3 2005 144 153 164 170 171 175 181 114,293 3609 37,446
United States 311.6 2000 102 112 119 124 175 167 162 154 183 205 204 210z 655,272 8608 51,689
Total 991.8 1,630,903 Mean 4440 38,897
Incidence* 140 140 140 151 159 160 164 D2.3% CAGR
Mean utilization ratey 140 140 140 151 159 160 164 D2.3% CAGR
Bold ﬁgures show summary.
Shaded values demonstrate the time interval of our analyses from 2005 to 2011.
Comments:
* Implants/100,000 total population.
y Implants/100,000 total population all ages.
z Rates calculated according to CAGR of implants of previous years.
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Table II
Utilization rate of patients aged 65 old and over per 100,000 total population from 2000 to 2011
Population
in 2011
[Mio]
Share of total
population [%]
Inpatient cases aged 65 years old and over per 100,000 total population Total number
of implants
in 2011
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Australia 3.1 14 101 108 111 114 116 115 116 118 117 122 123 125z 27,808
Austria 1.5 18 145 154 157 155 153 151 153 149 153 154 12,972
Belgium 1.9 17 138 138 140 143 134 137 136z 15,046
Canada 5.0 15 63 65 77 82 85 90 89 89 89 89 89 89z 30,604
Denmark 1.0 17 109 112 128 124 132 137 137 136 126 146 136 136z 7565
Estonia 0.2 17 54 49 49 51 49 52 51 50 48 643
Finland 1.0 18 117 119 124 127 119 132 136 125 132 127 131 126 6789
France 10.8 17 132 134 136 135 133 135 134 135 136 138 138 138 87,284
Germany 16.9 21 134 133 134 137 138 138 138 112,881
Hungary 1.7 17 70 69 59 62 61 58 68 6781
Ireland 0.5 12 118 113 119 119 120 125 124 118 110 105 105 101 4623
Israel 0.8 10 46 51 48 50 51 51 52 54 54 52 53 53z 4132
Italy 12.4 21 70 72 73 75 76 76 76 76 76 77 77 46,757
Korea 5.7 11 12 n/a 12 16 15 16 16 15 7467
Luxembourg 0.1 14 132 139 151 150 155 150 146 158 149 148 140 154 798
Mexico 6.6 6 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Netherlands 2.7 16 123 127 134 138 138 135 134 134 137 136 140 141z 23,473
New Zealand 0.6 13 101 99 92 89 108 111 110 117 114 113 110 106 4669
Norway 0.8 15 113 124 126 143 131 138 134 158 158 164 169z 174z 8634
Poland 5.3 14 31 35 34 38 43 47 55 21,189
Portugal 2.0 19 44 47 52 46 47 45 47 47 48 49 50z 51z 5371
Slovenia 0.3 17 101 111 102 113 110 95 112 2299
Spain 8.0 17 43 46 48 48 49 52 53 56 55 55 58 58 26,781
Sweden 1.8 19 121 121 121 125 131 130 121 11,433
Switzerland 1.3 17 154 161 165 167 171 177 177 172 175 180 14,242
United Kingdom 10.5 17 93 99 106 109 108 110 112 70,879
United States 41.4 13 82 90 96 100 141 135 130 123 144 159 156 160z 498,095
143.6 14 1,059,216
Incidence* 95 94 93 100 105 105 107 D1.6% CAGR
Mean utilization ratey 707 692 676 720 748 737 738 D0.6% CAGR
Bold ﬁgures show summary.
Shaded values demonstrate the time interval of our analyses from 2005 to 2011.
Comments:
n/a e not available.
* Implants/100,000 total population.
y Implants/100,000 aged 65 years old and over.
z Rates calculated according to CAGR of implants of previous years.
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Utilization rates vary
Utilization rates vary between individual OECD countries by a
factor of 38. Similar ﬁndings were shown for knee arthroplasty but
not for hip arthroplasty14: Although these differences might be
explained by national and regional factors, no correlation with
economic data was published up to now.
Different access to care due to economic factors
Economical factors such as GDP and health care expenditures
could be identiﬁed in our study to correlate signiﬁcantly with uti-
lization rates. Additionally incentives of a hospital payment system
(i.e., fee for service vs global budgets vs DRG-based payments) or
budgetary restrictions have an inﬂuence15. Nursing by family
members might also reduce the willingness for patients to undergo
an operation: More than one in 10 adults provides care to frail
people in Spain, where utilization rate is 40% below mean OECD
rate, but GDP is only 14% below mean OECD rate16. Access to
“essential care” according to United Nations’s deﬁnition in all re-
ported countries is 100%, with the exemption of Mexico, where 46%
is reported, explaining low rates12.
Amajor break in the growth of health expenditurewas observed
in Ireland and Estonia, with a simultaneous decrease in utilization
rates of hip arthroplasty, presumably due to the economic crisis. No
explanationwas found in Portugal, where utilization rate increaseddespite expenditures reducing signiﬁcantly17. In countries with
stable health expenditures, a negative correlation between total
utilization and growth rate was observed. Countries with a low
utilization rate like Korea and Poland tried to catch up and present a
high annual growth rate.
Increasing CAGR of countries
This leads to an increasing utilization rate of hip arthroplasty in
OECD countries, especially in younger patients, which corresponds
to register data. Between 2003 and 2011 in Australia there has been
an 18% increase in patients aged 55e64 years and an 11% increase in
patients younger than 55 years receiving a total hip replacement18.
In Sweden from 1994 to 2011 the number of men andwomen of age
70 and below receiving hip arthroplasty showed an increase of 16%
and 23%, respectively19. In contrast in England there was a slight
decrease of mean implantation age from 67.2 years in 2011
compared to 66.7 years in 200920.
Increasing CAGR of young
In absolute ﬁgures, there are less joint replacements performed
in patients younger than 65 years as compared to patients aged 65
years and older, but CAGR of “mean utilization rate” is seven times
higher in younger population than in older ones. In OECD countries
more and more citizens reach the age of 65. There is a three fold
difference between CAGR of population over 65 years versus
younger population with 1.6% versus 0.5%, respectively. But
Table III
Utilization rate of patients aged 64 old and under per 100,000 total population from 2005 to 2011
Population in
2011 [Mio]
Share of total
population [%]
Inpatient cases aged 64 years old and under per 100,000 total population Total number of
implants in 2011
2005 2006 2007 2008 2009 2010 2011
Australia 19.25 86 33 35 37 37 41 44 46z 10,255
Austria 6.93 82 96 101 106 110 111 117 119 9990
Belgium 9.1 83 99 98 99 102 96 99 98z 10,822
Canada 29.5 86 27 30 30 33 35 36 38z 13,040
Denmark 4.6 83 69 72 74 72 90 89 93z 5178
Estonia 1.1 83 32 35 36 38 37 35 34 452
Finland 4.4 82 79 84 81 88 88 95 99 5307
France 52.4 83 82 81 82 84 85 87 92 57,873
Germany 64.9 79 121 127 134 140 145 146 148 120,815
Hungary 8.3 83 40 40 36 39 39 38 47 4687
Ireland 4.0 88 13 11 11 10 12 15 17 783
Israel 7.0 90 <1 <1 <1 <1 <1 <1 <1 n/a
Italy 48.3 80 72 76 77 77 77 79 80 48,336
Korea 44.1 89 0z 0 0z 1 1 2 2 1145
Luxembourg 0.4 86 70 70 75 70 71 66 74 383
Mexico 102.6 94 n/a n/a n/a n/a n/a n/a n/a n/a
Netherlands 14.0 84 56 59 62 67 71 76 13,197
New Zealand 3.8 87 22 25 29 30 32 33 35z 1533
Norway 4.2 85 65 63 73 74 78 81 84z 4157
Poland 33.3 86 9 12 12 14 15 16 20 7859
Portugal 8.6 81 32 35 34 37 39 40 42z 4412
Slovenia 1.7 83 56 64 62 71 72 63 75 1537
Spain 38.2 83 35 36 37 36 38 40 44 20,224
Sweden 7.6 81 89 89 91 95 103 107 112 10,583
Switzerland 6.6 83 99 103 112 115 124 129 126 9946
United Kingdom 52.8 84 51 54 58 61 63 65 69 43,414
United States 270.2 87 32 32 31 39 46 48 50z 157,177
Total 848.2 86 571,686
Incidence* 44 45 46 50 53 54 57 D3.8% CAGR
Mean utilization ratey 51 52 53 58 62 63 66 D3.9% CAGR
Bold ﬁgures show summary.
Shaded values demonstrate the time interval of our analyses from 2005 to 2011.
Comments:
n/a e not available.
* Implants/100,000 total population.
y Implants/100,000 aged 64 years old and under.
z Rates calculated according to CAGR of implants of previous years.
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growing faster. CAGR of mean utilization rate in younger patients is
seven fold higher when compared to older patients (3.9% versus
0.6%). Improved longevity may be the reason that hip arthroplasty
has been described as “the operation of the 20th century”21.
The increasing use of THA in younger patients is also a sign for a
better accessibility to THA for patients independently from age,
since countries with a lower total utilization rate showed an even
lower utilization rate in younger patients, which means, that in23% 
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Fig. 1. Increase of population and total utilization of hip arthroplasty from 2005 to
2011.those countries older patients are preferred candidates for THA.
This may be due to limited economic resources.“Mean utilization rate” as a new parameter
In this context it becomes obvious that mean utilization rate can
not be described accurately for different age groups by using the
term “incidence”, because using total population in the denomi-
nator would disguise this ﬁnding: A six fold utilization rate in the
group of older patients as compared to younger ones is mathe-
matically reﬂected by an only 30% higher incidence, as demon-
strated in the example of Austria. We therefore point out that
whenever groups of patients with a different number of patients
in each group are compared, numerator and denominator should
refer to the same group and the introduced “mean utilization
rate” shall be used, as described in the methods above.Increasing revisions
After THA, a lifelong implant survival is desirable. Nevertheless a
variety of complications can occur, such as early infections or late
aseptic loosening, which are reﬂected in KaplaneMeier implant
survival curves for total hip replacements, varying from 90 to 96% at
10 years, according to ﬁxation type and age groups22. Both,
increasing life expectancy and a higher mean utilization rate in the
younger population, will result in higher revision rates in the future.
In a register study of the Nordic Arthroplasty Register Association
database including 536,962 hips, operated on between 1995 and
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Fig. 2. CAGR and population development in OECD countries from 2005 to 2011.
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was only slightly higher as compared to older patients (90.0e92.4%
as compared to 90.7e95.9%), according to cementation technique
used22. But in a previous study based on the Finnish Arthroplasty
Register, the 10-year implant survival of patients operated on be-
tween 1987 and 2006 who were younger than 55 years ranges be-
tween 79% and 80%, respectively23. As a consequence implantations
in younger patients will increase the demand for revision hip
arthroplasty in the group of older patients in the future.
But revision rate is not only a function of the age of patients and
other patient speciﬁc factors, but also of the type of prostheses
used. As more implants will be revised in the future, the choice of
which implant will become more critical. Furthermore, health care
budgets in OECD countries will be subjected to more pressure as
more costly revision surgeries increase4.
Limitations of the study
OECD health data is currently the most comprehensive database
for aggregated health measures worldwide, in particular due to
speciﬁc utilizationmeasures such as the number of hip arthroplasty0 
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Fig. 3. Box plot of hip arthroplasty utilization rate per 100,000 population in OECD
countries from 2000 to 2011.procedures. However data need to be reviewed carefully for the
purpose of cross-country analyses because it can be affected by
different drawbacks. Firstly, procedure coding systems vary to a
large extent across countries. Therefore the common ICD-9-CM
catalogue needs to be translated into country speciﬁc codes in or-
der to identify similar patients in national databases. Secondly,
OCED captures just a part of the world and we were not able to
incorporate data from non-OECD countries such as BRICS countries
(Brasil, Russia, India, China and South Africa). Thirdly, data from
small private institutions, who do not report to national govern-
mental institutions are not captured by OECD data, however, ac-
cording to OECD and registries, over 95% of all procedures in the
participating countries are reported and validated and therefore a
possible selection bias is negligible.
Conclusion
We observed a 38-fold variation in the utilization of hip
arthroplasty among OECD countries, ranging between eight and
306 cases per 100,000 population. These ﬁndings can be explained
by differences in health expenditure and correlate well with GDP
per capita. There is a signiﬁcant increase of utilization rate in most
countries. Furthermore there is a seven fold difference in growth
rate between mean utilization rate of younger and older patients.
The higher growth rate in younger patients in recent years will
consequently lead to an increase in the number of revisions in the
upcoming years in older patients.
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total utilization rate of hip arthoplasty per 100.000 population in 2011
 (Pearson's correlation, r = .764, p<.001)   
Fig. 4. Correlation of health care expenditures per capita and utilization rate of hip arthroplasty.
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